MiTAC Computing Technology USA Corporation Announces Grand Opening of Expanded Newark Office to Drive U.S. Infrastructure Growth
NEWARK, Calif., Aug. 11, 2026 /PRNewswire/ -- MiTAC Computing Technology Corporation, a global leader in high-performance, energy-efficient server solutions and a subsidiary of MiTAC Holdings Corporation (TWSE:3706), announced the grand opening of...
Vield Announces Strategic Cyber Security Partnership with Revio to Bolster Defence-in-Depth Infrastructure
SYDNEY, Aug. 11, 2026 /PRNewswire/ -- To address the growing need for institutional-grade security and independent oversight in the digital asset sector, Vield, an Australian Bitcoin-backed finance company, today announced a strategic partnership...
GIGABYTE Announces the Availability of AORUS GeForce RTX™ 50 INFINITY Series Graphics Cards
TAIPEI, Aug. 10, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, announces the availability of the AORUS GeForce RTX™ 5080, RTX™ 5070 Ti, and RTX™ 5070 INFINITY graphics cards. Designed for enthusiasts seeking uncompromised...
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.81 Million Tokens, and Total Crypto and Total Cash Holdings of $11.6 Billion
Bitmine owns 4.8 % of the total ETH coin supply of 120.7 million Bitmine is 96 % of the way to the 'Alchemy of 5%' in just 14 months In July, ETH outperformed Nasdaq 100 by 2,500 basis points, the largest since July 2025, reflective of the...
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a...
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo...
SweetNight Announces Brand Renewal Ahead of the Debut of the CoolNest® Ultra, the Latest Addition to Its CoolNest® Series
WILMINGTON, Del., Aug. 8, 2026 /PRNewswire/ -- SweetNight, a sleep wellness brand focused on accessible premium comfort solutions, today announced a comprehensive brand renewal—including an updated logo, redesigned visual identity system, and...
SuperX Announces Progress on Share Repurchase Program, Initiates New Buyback Plan to Reinforce Confidence in Long-Term Growth Value
SINGAPORE, Aug. 7, 2026 /PRNewswire/ -- SuperX AI Technology Limited (Nasdaq: SUPX, the "Company" or "SuperX"), a provider of AI infrastructure solutions, today announced an update on the progress of its share repurchase program and the adoption of...
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
SINGAPORE, Aug. 7, 2026 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai International" or the "Company"), one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi...
Coway Announces Financial Results for Q2 FY2026
SEOUL, South Korea, Aug. 7, 2026 /PRNewswire/ -- Coway Co., Ltd., the "Best Life Solution Company," announced its financial results for the second quarter of 2026. Coway Financial Results (2Q 2026) "In the second quarter, we demonstrated strong...